Academic literature on the topic '(477.54) "1917'

Background The current advancement and increasing use of diagnostic imaging has led to increased detection of abdominal aortic aneurysms (AAA). Many of these patients are unfit for elective AAA surgery. Aim To investigate the outcome of conservative management of unfit patients with large AAA (>5.5 cm) who are turned down for elective surgical intervention. Patients and methods Between January 2006 and April 2017, 457 patients presented with AAA >5.5 cm. Seventy-six patients (M: F 54:22) were deemed unfit for elective repair. Mean age was 79.8 years (range 64–96). Mean AAA size was 60.22 mm (55–83). Results Forty-nine of the 76 patients (64%) had died by April 2017. Fifteen (19.7%) patients died directly because of their aneurysm rupture. A further 34 (44.7%) patients died from non-aneurysm-related causes. Conclusion Patients with large AAA deemed unfit for elective surgery have an overall poor prognosis and die mainly from other causes than AAA. Surgical intervention when rupture occurs results in poor survival.

Context.— Biomedical terminologies such as Logical Observation Identifiers, Names, and Codes (LOINC) were developed to enable interoperability of health care data between disparate health information systems to improve patient outcomes, public health, and research activities. Objective.— To ascertain the utilization rate and accuracy of LOINC terminology mapping to 10 commonly ordered tests by participants of the College of American Pathologists (CAP) Proficiency Testing program. Design.— Questionnaires were sent to 1916 US and Canadian laboratories participating in the 2018 CAP coagulation (CGL) and/or cardiac markers (CRT) surveys requesting information on practice setting, instrument(s) and test method(s), and LOINC code selection and usage in the laboratory and electronic health records. Results.— Ninety of 1916 CGL and/or CRT participants (4.7%) responded to the questionnaire. Of the 275 LOINC codes reported, 54 (19.6%) were incorrect: 2 codes (5934-2 and 12345-1) (0.7%) did not exist in the LOINC database and the highest error rates were observed in the property (27 of 275, 9.8%), system (27 of 275, 9.8%), and component (22 of 275, 8.0%) LOINC axes. Errors in LOINC code selection included selection of the incorrect component (eg, activated clotting time instead of activated partial thromboplastin time); selection of panels that can never be used to obtain an individual analyte (eg, prothrombin time panel instead of international normalized ratio); and selection of an incorrect specimen type. Conclusions.— These findings of real-world LOINC code implementation across a spectrum of laboratory settings should raise concern about the reliability and utility of using LOINC for clinical research or to aggregate data.

e17081 Background: Biomarkers to select mRCC patients most likely to benefit to immunotherapy are needed. The retrospective multicentre Meet-URO-15 study evaluated the prognostic role of peripheral blood cells in mRCC patients treated with Nivolumab. Methods: Complete blood count was assessed at the first four cycles of Nivolumab. The primary endpoint was median overall survival (mOS) according to bNLR. NLR was defined as neutrophil / lymphocyte (cutoff = 3) and ΔNLR the difference between NLR at 2nd cycle and bNLR (median as cutoff = 1.1). Results: From October 2015 to October 2019, 470 patients started Nivolumab as 2nd (67%), 3rd (22%) and > 3rd (11%) line. Median age was 66 years, 71% were male and 83% had clear cell histology. Baseline IMDC group was favorable in 25%, intermediate in 63% and poor in 12%. Lymph-nodes, visceral and bone metastases were present in 54%, 91% and 36%. mOS and progression-free survival (PFS) were 34.8 and 7.5 months. Overall response rate (ORR) and disease control rate (DCR) were 30% and 61%. bNLR was available in 404 patients: bNLR < 3 (54%) correlated with statistically significant longer PFS [11.4 vs 5.4 months; HR 1.69 (1.33-2.15)] and OS [46.2 vs 17.2 months; HR 2.37 (1.72-3.26)] (both p< 0.001), with similar ORR (35% vs 30%, p= 0.28) but higher DCR (71% vs 52%, p< 0.001). ΔNLR was available in 360 patients: ΔNLR < 1.1 (73%) correlated with a statistically significant improvement of PFS [11.2 vs 4.9 months; HR 1.53 (1.16-2.03), p= 0.03], OS [Not Reached vs 19.7 months; HR 1.83 (1.28-2.61), p= 0.001], ORR (37% vs 23%, p= 0.011) and DCR (68% vs 53%, p= 0.008). Multivariate analyses adjusted for IMDC group, line of therapy and metastatic sites, confirmed the statistically significant correlation of bNLR and ΔNLR with OS, PFS and DCR. Conclusions: Our study showed the statistically significant correlation of lower bNLR and early ΔNLR with longer OS, PFS and higher DCR in mRCC patients treated with Nivolumab.

Objetivou-se neste estudo diagnosticar o estado nutricional da Equipe Olímpica Permanente de Levantamento de Peso do Comitê Olímpico Brasileiro (COB). A amostra foi composta por 24 atletas, na faixa etária entre 16 e 23 anos, sendo 12 do sexo masculino (19,7 ± 2,4 anos) e 12 do feminino (19,2 ± 1,8 ano). Realizou-se o seguinte procedimento para o diagnóstico do estado nutricional: análise da adequação da ingestão de energia e dos macronutrientes - carboidratos (CHO), lipídios (LIP) e proteínas (PRO) -, por meio dos métodos Recordatório de 24 horas e Questionário de Freqüência de Consumo Alimentar, além da caracterização do perfil antropométrico. Os resultados da avaliação dietética indicaram que a distribuição energética entre os macronutrientes encontra-se adequada sendo de 54 ± 6,8% (CHO); 28,5 ± 5,9% (LIP); e 14,5 ± 3,4% (PRO) para os homens e 56,3 ± 4,7% (CHO); 28,6 ± 4,6% (LIP); e 13,7 ± 2,4% (PRO) para a equipe feminina. Entretanto, quanto ao consumo energético total, 83% dos atletas estavam com ingestão energética abaixo dos valores recomendados, considerando o alto nível de atividade física, promovendo deficiência calórica diária. O percentual de gordura corporal dos atletas do sexo masculino (3,6 ± 0,7%) indicou que todos estavam abaixo do padrão de referência, enquanto 58% dos esportistas do sexo feminino apresentavam excesso de gordura (17,9 ± 5,8%). Tem-se, como conclusão, que, apesar de os desportistas avaliados terem realizado distribuição energética adequada entre os macronutrientes, esta ainda não foi suficiente para suprir as exigências energéticas da modalidade, necessitando assim de orientação nutricional.

Background: Menopause, the point in a woman’s life when permanent cessation of cyclical menstruation occurs for a period of 12 months due to the loss of ovarian activity marking the end of reproductive lifespan and potential. Natural menopause is a physiological event, universal women phenomenon and irreversible part of the entire normal aging process. It brings the menopausal woman for preventive health care services due to its associated health implications. This study sought to investigate the age at menopause and its correlates in southern Nigerian women.Methods: A cross-sectional survey of datasets of women from two different communities attending annual religious conference was conducted using tested semi-structured researcher-administered questionnaire in 2019.Results: Data was analyzed on 152 participants from an urban and a rural communities. Mean chronological age was 58.8±8.8 years and parity was 6.4±2.2. Mean age at menopause was 50.0±4.6 years, median (IQR) 50.0 (47-53) and 49.2±4.7 versus 50.5±4.5 and median (IQR) 49.5 (46-51) and 50.5 (47-54) for urban and rural participants respectively. 1.3%, 9.2%, 69.7% and 19.7% were premature, early, normal and late onset menopause respectively. Risk of early onset menopause was insignificantly increased by higher education, social class, lower BMI and low parity. Forgetfulness (20.3%), irritability (19.5%), hot flushes (17.3%) and insomnia (16.5%) were the leading symptoms. Main complications were chronic hypertension 62 (40.8%), diabetes mellitus 12 (7.9%) and 4 (2.6%) recent fractures.Conclusions: Age at menopause was moderate, early menopause was rather high, programmed preventive healthcare services should address modifiable risk factors. Cancer screening services for late onset women is equally crucial.

Background: COVID-19 pandemic has challenged the healthcare resources globally, inspiring the need for identifying simple, economical biomarkers. COVID-19 is an immune-inflammatory disorder and systemic inflammatory index (SII) derived from the peripheral blood has been proposed as a marker.Methods: Retrospective study of severe COVID-19 hospitalized patients (total N=154 including diabetic subset N=57). Data regarding hematological variables such as absolute neutrophil count (ANC), absolute lymphocyte count (ALC), platelet count along with thrombo-inflammatory proteins, D-dimer, C-reactive protein (CRP) were extracted from medical records. SII was calculated from ANC×platelets/lymphocyte count. Clinically applicable cut-offs were derived using the receiver operating characteristic curve (ROC) analysis for SII, CRP and D-dimer. Correlations between hematological parameters and D-dimer, CRP were analyzed to validate them as biomarkers of thrombo-inflammation and as predictors of clinical outcome.Results: Among 154 severe COVID-19 patients, significant association with mortality was seen with respect to ANC (p<0.001), SII (p=0.01), CRP (p=0.004) and D-dimer (p=0.001). In the total COHORT, based on ROC curve, applicable cut-off for outcome prediction were for SII 14.85×105 (area under curve (AUC)-0.691, sensitivity-67%, specificity-64%,odds ratio (OR)-3.44), CRP 19.7 mg/l (AUC-0.718, OR-5.71), D-dimer 0.285 mcg/ml (AUC-0.773, OR-6.94) respectively. In the diabetic subset, the cut-offs for SII 14.85×105 (AUC-0.68, sensitivity-80%, specificity-54%, OR-4.7), CRP 52.5 mg/l (AUC-0.723, OR-5.36) and D-dimer 0.285 mcg/ml (AUC-0.771, OR-11.3) respectively.Conclusions: Clinically applicable thresholds for SII serve as reliable biomarkers of thrombo-inflammation and prognosis in severe COVID-19 patients. Diabetic patients with similar thresholds had higher risk and prediction for mortality. In the resource constrained health care settings, who might not afford D-dimer, SII may serve as an economical bio-maker.

Abstract Background. OM is a common toxicity of conditioning regimens for HSCT that has been associated with adverse clinical and economic outcomes. Methods. A retrospective chart review study of ~400 consecutive HSCT recipients was undertaken at a single academic center. OM severity was assessed across eight oropharyngeal sites using a validated scale which was scored as follows: no erythema/ulceration = 0; erythema only = I; ulceration one site = II; two sites = III; three sites= IV; and four or more sites = V. OM assessments began on the day of conditioning and continued bi-weekly until hospital discharge. Outcomes of interest included number of days of fever, total parenteral nutrition (TPN), and parenteral narcotic therapy, incidence of grade III or IV (Common Toxicity Criteria) infection, and inpatient days and charges. We report data here for the 115 MM patients in the study cohort who underwent AU HSCT after high-dose MP conditioning. Results. Mean age was 54 yrs. Seventeen percent of patients received total body irradiation. Bone marrow was the source of most grafts. Forty-eight percent of patients experienced OM ≥ grade II. The relationship between worst recorded grade of OM and each of the outcomes of interest is reported below. Conclusions. OM is associated with worse clinical and economic outcomes in MM patients undergoing AU HSCT following high-dose MP conditioning. Outcomes of AU HSCT following high-dose MP conditioning for MM, by worst recorded grade of OM Worst Grade of OM (N=115) 0 I II III IV V *mean, SD; **test for linear trend; Cochran-Armitage for dichotomous measures, GLM for continuous measures Outcome n=37 n=23 n=24 n=15 n=8 n=8 -value p Fever days* 1.2 (2.8) 2.5 (3.1) 2.1 (2.3) 1.9 (1.4) 3.0 (2.1) 3.6 (6.2) 0.057 TPN days* 0.0 (0.0) 0.1 (0.4) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 2.3 (6.0) 0.003 Narcotic days* 1.5 (3.1) 4.7 (3.8) 4.6 (4.4) 4.4 (3.7) 7.9 (3.3) 9.9 (7.4) <0.001 Infection, % 51.4 73.9 62.5 80.0 100.0 75.0 0.014 Mortality, % 0.0 0.0 4.2 0.0 0.0 12.5 0.085 Inpatient days* 18.6 (3.4) 21.0 (3.5) 19.6 (3.6) 19.7 (2.3) 23.3 (2.4) 23.4 (5.6) <0.001 Inpatient charges* (x 1,000 USD) 119 (36) 130 (35) 118 (25) 121 (28) 141 (31) 184 (92) <0.001

Background:Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting the musculoskeletal system as well as skin and nails. The prevalence of depression in psoriasis and PsA is high and ranges from 7-40% [1]. Persistent depressive mood may influence disease activity outcome in PsA, especially patient-reported outcomes.Objectives:To assess the correlation of depressive symptoms with PsA-specific outcome parameters.Methods:RABBIT-SpA is a prospective longitudinal cohort study including PsA patients enrolled at start of a new conventional treatment or b/tsDMARD treatment. In regularly provided follow-up questionnaires, physician- and patient-reported information on the disease course including the depression screening tool WHO-5 to assess mental health is collected. For the current analysis, the WHO-5 score was categorised into 4 groups using validated cut-offs: severe depressive symptoms <13, moderate depressive symptoms 13-28, mild depressive symptoms 29-50, well-being >50. Spearman correlation coefficient was calculated to analyse the relationship between the WHO-5 score and various PsA related outcome parameters.Results:936 PsA patients were included. Baseline characteristics are shown in Table 1. In 411 patients (43.9%) the WHO-5 score indicated well-being, 249 (26.6%) had mild depressive, 203 (21.7%) moderate depressive and 73 patients (7.8%) severe depressive symptoms. WHO-5 results correlated with patient reported skin involvement (DLQI: -0.25, patient assessment skin: -0.17), and the composite scores DAPSA (-0.33) and DAS28 (-0.28) as well as with patient reported pain (-0.43) and patient global disease assessment (-0.42). The highest correlation was found for physician assessed global health status (-0.51) and PSAID (-0.62). No significant correlation was found with CRP, swollen joint count and physician assessed skin involvement including body surface area (BSA).Table 1.Baseline characteristics of patients included in the analysis stratified by WHO-5 categories.ParameterWHO-5 (<13) severeN=73WHO-5 (13-28) moderateN=203WHO-5 (29-50) mildN=249WHO-5 (>50) well-beingN=411TotalN=936Age, mean (SD)52.6 (11.4)51 (11.3)51.4 (12.5)52.8 (12.7)52 (12.2)Female, n (%)52 (71.2)127 (62.6)157 (63.1)227 (55.2)563 (60.1)Disease duration, years, mean (SD)8.3 (8.7)6 (7.9)6.2 (6.7)6.4 (7.5)6.4 (7.5)Dactylitis, n (%)14 (19.7)31 (15.5)46 (18.5)77 (18.8)168 (18.1)Axial involvement, n (%)14 (19.7)54 (26.9)49 (19.7)71 (17.3)188 (20.2)Nail involvement, n (%)34 (47.2)85 (42.3)106 (42.6)158 (38.6)383 (41.1)BMI>=30, n (%)37 (51.4)75 (37.1)98 (39.5)125 (30.9)335 (36.2)CRP of >=5 mg/L, n (%)33 (51.6)84 (45.4)99 (46.5)138 (39.1)354 (43.4)BSA (0-100), mean (SD)10.1 (18.3)9.5 (16.8)8.5 (14.9)8.1 (14.6)8.7 (15.5)Physician assessed global health (NRS 0-10), mean (SD)6.3 (1.5)5.6 (1.8)5.2 (1.7)4.9 (1.9)5.2 (1.9)TJC68, mean (SD)9.9 (7.1)8.6 (7.6)8.2 (7.6)7.3 (8.2)8 (7.8)SJC66, mean (SD)6 (5.2)4.8 (4.9)4.7 (4.4)4.3 (3.8)4.6 (4.4)DAPSA, mean (SD)29.3 (11.1)25.1 (12.9)23.4 (12.1)18.9 (12.4)22.3 (12.8)DAS28-CRP, mean (SD)4.1 (1)3.8 (1.2)3.7 (1.1)3.2 (1.1)3.6 (1.2)Patient assessed global health (NRS 0-10), mean (SD)7.9 (2.1)6.6 (2.1)5.9 (2)4.8 (2.3)5.7 (2.4)Patient assessed pain (NRS 0-10), mean (SD)7.8 (1.8)6.4 (2.1)5.8 (2)4.6 (2.4)5.5 (2.4)DLQI (0-30), mean (SD)8.5 (8.2)7.8 (7.2)5.4 (5.7)4.1 (4.9)5.6 (6.2)PSAID (0-10), mean (SD)6.9 (1.8)5.5 (1.8)4.4 (1.7)3 (1.7)4.2 (2.2)Conclusion:The impact of depressive symptoms on outcome parameters used in rheumatology is increasingly being recognised. Interestingly, direct measures of inflammatory disease activity of joint and skin disease such as BSA, CRP, and swollen joint count were not correlated with depressive symptoms. The highest correlation was found for broader assessments like global health status and PSAID.References:[1]Haugeberg et al. Arthritis research & Therapy, 2020, 22:198Acknowledgements:RABBIT-SpA is supported by a joint, unconditional grant from AbbVie, Amgen, Biogen, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB and Viatris.We thank all participating rheumatologists and patients.Disclosure of Interests:Anne Regierer Grant/research support from: AbbVie, Amgen, Biogen, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB and Viatris., Anja Weiß Grant/research support from: AbbVie, Amgen, Biogen, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB and Viatris., Martin Bohl-Buehler: None declared, Xenofon Baraliakos: None declared, Frank Behrens: None declared, Georg Schett: None declared, Anja Strangfeld Grant/research support from: AbbVie, Amgen, Biogen, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB and Viatris.

This research is a part of the analysis of the collection of articles of the Latvian Literary Society (Lettisch-literärische Gesellschaft) Magazin, herausgegeben von der Lettisch-Literärischen Gesellschaft (so-called “Magazin”) with special emphasis to the materials important in the history of Latvian language, especially, of the development of terminology in Latvian. This paper deals with the almost forgotten author Pēteris Zēvalds (Peter Seewald) (ca. 1838/1839–1910), a schoolteacher in Jelgava (Mitau) and active contributor of “Magazin” from 1865 to 1877. In 12 sequels (published in eight issues of “Magazin”), he collected 2198 words and expressions from his native place, now Birzgale parish, originally, from the private manor in Linde parish (aus Privatgut Lindenschen Gemeinde in Kurland)). This paper provides a more detailed analysis of two other word collections (both published in 1874 in issue 3 of XV volume of “Magazin”) of Zēvalds. They contained current lexis, including a lot of new terms. The first one is created as a successive excerpt of neologisms and lesser-known words (in Latvian-German comparison) from the weekly newspaper “Baltijas Vēstnesis” (using numbers 44th, 48th, 49th un 51st from 1872 and successive first 49 from 1873, excl. number 9th). There are 467 numbered entries or 495 words in total. Most of the words in Zēvalds’s collection are related to terminological lexis. They can be divided into four groups (indicating the serial number used in the original): (1) terms currently used in the same form or with minor changes of ending (7. greizsirdība, 29. pilnvare, 41. māksla, 33. cēlons, 69. veicināšana, 88. pirmvaloda, 237. izvilktne (= atvilktne), 275. viels); (2) terms which have a different correspondence in modern Latvian (32. valodas=iztirzāšana (= valodniecība), Sprachforschung; 49. lietuve (= lejkanna), Gieskanne; 54. rakstiens (=raksts, dokuments), Schriftstück; 183. atvēles=zīme (= atļauja), Erlaubnißschein; 187. jūras=pāržmauga (= jūrasšaurums), Meerenge); (3) words, that could still be considered as potential terms (11. tiesas=laulība, Zivilehe; 37. sauljumte, Sonnenschirm) and (4) those, which, from the moment of fixation, can be considered occasional words (43. spīdgans, Sternschnuppen, Meteor; 387. muldu=valsts, Reich der Träume; 409. tulpete (= runas=vieta), Katheder, Rednerbühne). Zēvalds’s collection is a unique material that allows identifying the perception of the interested reader about the lexical neologisms in one newspaper. Zēvalds’s second collection of words contains the technical expressions from legal country house purchase agreements. There are 83 numbered entries (in German-Latvian comparison) from the legal contract written in German with a lot of additional conditions and long pay-outs delay. This list (at least the part containing legal terms and terminological word-groups) can be regarded as the first term bulletin in Latvian. The possible addressee of this term list is the parish pastors to whom farmers sought advice on such matters. Publications of the teacher Pēteris Zēvalds is a small but interesting episode in the history of the Latvian language, which has not earned attention so far but provides researchers with interesting material about the lexical development in the 70s of XIX century.

We have developed a sandwich-type enzyme immunoassay (EIA) for the quantitation of fibrin degradation products (FbDP) in plasma with a time-to-result of only 45 minutes. The assay is based on the combination of the specificities of two monoclonal antibodies (FDP-14 and DD-13), developed in our institute. FDP-14, the catching antibody, binds both fibrinogen degradation products (FbgDP) and FbDP. It has its epitope in the E-domain of the fibrinogen molecule on the BB-chain between amino acids 54-118 (Blood 68, 437, 1986). Antibody DD-13 was raised using D-dimer as antigen and was used as a tagging antibody, conjugated with horse-radish peroxidase.A strong positive reaction is obtained with a whole blood clot lysate (lysis induced by tissue-type plasminogen activator) which is used as a standard.The EIA does not detect FbgDP i.e. purified fragments X, Y, D:E complexes or FbgDP in plasma treated in vitro with streptokinase. This indicates that the assay is specific for fibrin degradation products.We have successfully applied this assay to the plasma of patients with a variety of diseases. In combination with the assays previously developed by us for FbgDP (Thromb. Haemostas. 1987, in press) and for the total amount (TDP) of FbgDP + FbDP in plasma (J. Lab. Clin. Med. 1987, in press), we are now able to study the composition of TDP in terms of FbgDP and FbDP in patients.